

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



维亚生物科技控股集团
VIVA BIOTECH HOLDINGS

(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF JOINT-STOCK CONVERSION OF VIVA SHANGHAI
AND
CHANGE OF ROLES OF CO-CHIEF FINANCIAL OFFICER

This announcement is made by Viva Biotech Holdings (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

COMPLETION OF JOINT-STOCK CONVERSION OF VIVA SHANGHAI

The Company is pleased to announce that it was notified on September 27, 2024 that Viva Biotech (Shanghai) Ltd. (維亞生物科技(上海)有限公司, “**Viva Shanghai**”), a limited liability company established in the PRC and an indirect non-wholly owned subsidiary of the Company has completed the registration procedures with the State Administration for Market Regulation for its conversion into a joint-stock company with limited liability on September 26, 2024. Immediately upon completion of the joint-stock company conversion, Viva Shanghai will have a issued share capital of RMB446,018,390, and the Company is indirectly interested in RMB325,179,147 of its issued share capital, representing approximately 72.9071% of its entire issued share capital.

CHANGE OF ROLES OF CO-CHIEF FINANCIAL OFFICER

The Company further announces with effect from September 27, 2024, Mr. WANG Zheren (“**Mr. Wang**”) has tendered his resignation from the role of Co-Chief Financial Officer of the Group with effect from the date of this announcement. Mr. Wang will remain with the Group and continue to serve as the Chief Financial Officer of Viva Shanghai, and will be primarily responsible for leading Viva Shanghai’s financial management and strategic development, as well as serving as the secretary to the board of Viva Shanghai. The change in roles and responsibilities will enable Mr. Wang to focus more of his attention on leading the financial management and strategic development of Viva Shanghai.

Upon the proposed change in roles, Mr. XIONG Wei, the other Co-Chief Financial Officer of the Group, will assume the role as the Chief Financial Officer of the Group, and will primarily responsible for leading the Group's financial management and capital market related affairs. The Company confirms that there are no other matters required to be brought to the attention of the shareholders of the Company in relation to the change of roles of the Co-Chief Financial Officers.

By order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, September 27, 2024

As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. WU Ying and Mr. Ren Delin; two Non-executive Directors, namely, Mr. WU Yuting and Mr. Wang Stephen Hui; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.